8-K: Celldex Barzolvolimab Fails EoE Clinical Endpoint

Celldex Therapeutics announced that its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis met its primary endpoint of mast cell depletion but failed to show clinical improvement, leading to a halt in EoE development.

Summary

• The Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE) met its primary endpoint, demonstrating profound mast cell depletion in the gastrointestinal tract.
• Peak mast cell counts (CD117 positive cells) per high power field (hpf) at baseline were 50.3 in the placebo arm and 55.4 in the barzolvolimab 300mg Q4W arm.
• At Week 12, the absolute change from baseline was -2.7 for placebo compared to -36.0 for barzolvolimab [Diff (95%CI): -33.3 (-44.1, -22.6); p=<0.0001)].
• Despite the profound mast cell depletion, no definitive evidence of clinical improvement in EoE symptoms, as measured by the Dysphagia Symptom Questionnaire (DSQ) (p=0.33), or endoscopic assessment of disease activity (EREFS) (p=0.95) were observed compared to placebo.
• No difference was observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).
• Celldex will not advance Barzolvolimab development in the EoE indication based on these results.
• The results do support future development with KITor SCF-targeted therapies in other GI indications where mucosal mast cells are believed to play an important role.
• Barzolvolimab demonstrated a favorable safety and tolerability profile at the 300 mg Q4 weekly dosing regimen, consistent with prior studies.

Sentiment

Score: 4

Explanation: While the drug successfully demonstrated its mechanism of action by depleting mast cells and showed a favorable safety profile, the failure to achieve clinical improvement in Eosinophilic Esophagitis (EoE) is a significant setback for this specific indication, leading to the discontinuation of its development in EoE. However, the company's broader pipeline for Barzolvolimab in other indications (CSU, CIndU, PN, AD) remains active and promising, mitigating the overall negative impact.

Positives

• Barzolvolimab successfully met the primary endpoint of profound mast cell depletion in the gastrointestinal tract, demonstrating its mechanism of action with high statistical significance (p=<0.0001).
• The drug exhibited a favorable safety and tolerability profile at the 300 mg Q4 weekly dosing regimen, consistent with prior studies.
• The study provided direct evidence that mast cells are not a primary driver in EoE, advancing scientific understanding of the disease.
• Results support future development of KITor SCF-targeted therapies in other GI indications where mucosal mast cells are believed to play an important role.
• Enrollment is ongoing across four other studies for Barzolvolimab, including two Phase 3 studies in chronic spontaneous urticaria and Phase 2 studies in atopic dermatitis and prurigo nodularis.
• Plans are being finalized to initiate a Phase 3 program in inducible urticaria, which will include both cold urticaria and symptomatic dermographism.

Negatives

• Despite profound mast cell depletion, Barzolvolimab did not result in improved clinical outcomes for EoE symptoms (DSQ, p=0.33) or endoscopic assessment of disease activity (EREFS, p=0.95) compared to placebo.
• No difference was observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).
• Celldex will not advance Barzolvolimab development in the Eosinophilic Esophagitis indication.

Risks

• Ability to successfully complete research, further development, and commercialization of drug candidates, including Barzolvolimab, in current or future indications.
• Uncertainties inherent in clinical testing and accruing patients for clinical trials.
• Limited experience in bringing programs through Phase 3 clinical trials.
• Ability to manage and successfully complete multiple clinical trials and the research and development efforts for multiple products at varying stages of development.
• Availability, cost, delivery, and quality of clinical materials produced by own manufacturing facility or supplied by contract manufacturers, who may be sole source of supply.
• Timing, cost, and uncertainty of obtaining regulatory approvals.
• Failure of the market for the Company's programs to continue to develop.
• Ability to protect intellectual property.
• Loss of any executive officers or key personnel or consultants.
• Competition.
• Changes in the regulatory landscape or the imposition of regulations that affect the Company's products.
• Ability to continue to obtain capital to meet long-term liquidity needs on acceptable terms, or at all, including the additional capital necessary to complete initiated or planned clinical trials.

Future Outlook

Celldex will not advance Barzolvolimab in Eosinophilic Esophagitis but plans to continue its development in other indications, with ongoing enrollment in two Phase 3 studies for chronic spontaneous urticaria and Phase 2 studies for atopic dermatitis and prurigo nodularis. The company also plans to initiate a Phase 3 program in inducible urticaria, including cold urticaria and symptomatic dermographism, and explore other GI indications where mast cells are relevant.

Management Comments

• "As we explore barzolvolimab's full potential as a mast cell depleting agent, we are ultimately defining which diseases are mast cell driven." Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.
• "While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options." Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.
• "We remain focused on advancing the deep pipeline for barzolvolimab, with enrollment ongoing across four studies, including two Phase 3 studies in chronic spontaneous urticaria and Phase 2 studies in atopic dermatitis and prurigo nodularis, while we also finalize plans to initiate a Phase 3 program in inducible urticaria that will include both cold urticaria and symptomatic dermographism." Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.
• "We are deeply committed to driving innovation in mast cell science and delivering life-changing therapies for patients and look forward to advancing barzolvolimab and our growing pipeline of KITand SCF-targeting candidates into additional indications in the future." Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.

Industry Context

This announcement highlights the challenges in identifying primary disease drivers for complex inflammatory conditions like Eosinophilic Esophagitis. While mast cell depletion was achieved, its lack of clinical efficacy in EoE suggests that the disease pathogenesis is more complex than solely mast cell-driven, potentially involving other inflammatory pathways like eosinophils. This outcome contrasts with other mast cell-driven diseases where Barzolvolimab is showing promise, reinforcing the need for targeted approaches based on specific disease mechanisms.

Stakeholder Impact

• Shareholders: Potential negative impact due to the discontinuation of a development program for a specific indication, but mitigated by the continued progress in other indications.
• Patients (EoE): Disappointment as a potential new treatment option will not be pursued for Eosinophilic Esophagitis.
• Patients (Other indications): Continued hope for new therapies as Barzolvolimab development progresses in chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, and atopic dermatitis.
• Research Community: Valuable scientific insight gained regarding the role of mast cells in EoE pathogenesis, informing future research directions.

Next Steps

• Celldex will not advance Barzolvolimab development in Eosinophilic Esophagitis.
• Continue enrollment across four ongoing studies for Barzolvolimab (two Phase 3 studies in chronic spontaneous urticaria, Phase 2 studies in atopic dermatitis and prurigo nodularis).
• Finalize plans to initiate a Phase 3 program in inducible urticaria (cold urticaria and symptomatic dermographism).
• Explore future development with KITor SCF-targeted therapies in other GI indications where mucosal mast cells are believed to play an important role.
• Host a conference call/webcast on August 19, 2025, at 4:30 p.m. ET to discuss the results.

Key Dates

Recommendation

While the failure of Barzolvolimab in the Eosinophilic Esophagitis (EoE) Phase 2 study is a clear negative, leading to the discontinuation of development in this indication, the drug successfully demonstrated its mechanism of action (mast cell depletion) and a favorable safety profile. The company has a robust pipeline for Barzolvolimab in other mast cell-driven diseases, including two ongoing Phase 3 studies in chronic spontaneous urticaria and plans for a Phase 3 program in inducible urticaria. This diversified pipeline and the drug's demonstrated safety and mechanism of action in other contexts suggest that the overall value proposition is not entirely diminished, warranting a 'hold' as investors await further data from the more advanced programs.

Keywords

Barzolvolimab, Eosinophilic Esophagitis, EoE, Phase 2, Clinical Trial, Mast Cell Depletion, Celldex Therapeutics, Biotechnology, Drug Development, Inflammatory Disease, KIT inhibitor, Chronic Spontaneous Urticaria, Atopic Dermatitis, Prurigo Nodularis, Inducible Urticaria